Tatas eye biotech, ayurveda
The Rs 65,000-crore Tata Group is drawing up a fresh gameplan which will see it diversify into life sciences including biotechnology and ayurveda, and financial services with a thrust on retail.
The Rs 65,000-crore Tata Group is drawing up a fresh gameplan which will see it diversify into life sciences including biotechnology and ayurveda, and financial services with a thrust on retail.